Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis

Company Overview

Phio Pharmaceuticals, Inc. (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion. The lead programs in its pipeline include PH‐762, being evaluated in collaboration with Janssen for solid tumor indications, and PH‐687, an internally developed candidate with potential in immuno‐oncology. Both candidates are currently in preclinical or early clinical testing, as the company seeks to validate safety, tolerability and proof-of‐mechanism in human studies.

In addition to its collaboration with Janssen, Phio has established partnerships with academic institutions and research organizations to explore the broader utility of TRiMTM in hard‐to‐treat cancers. The company’s R&D efforts are supported by preclinical data demonstrating potent gene knockdown and immune modulation, laying the groundwork for combination strategies with established immunotherapies.

Founded in 2014 and headquartered in Newtown, Pennsylvania, Phio Pharmaceuticals operates primarily in the United States while engaging with global research networks. The company is led by President and Chief Executive Officer Seth Hewitt, whose background in translational oncology and RNAi drug development guides Phio’s strategic direction and clinical advancement efforts.

Key Stats

• Today's Range: $2.08 to $2.17
• 50-Day Range: $1.97 to $2.74
• 52-Week Range: $0.97 to $9.79
• Volume: 43,655 shs
• Average Volume: 3.64 million shs
• Market Capitalization: $12.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

Phio Pharmaceuticals Stock Analysis - MarketRank™

Phio Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 522nd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Phio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Phio Pharmaceuticals has a consensus price target of $14.00, representing about 552.7% upside from its current price of $2.15.

Amount of Analyst Coverage

Phio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($8.54) to $3.76 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Phio Pharmaceuticals is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Phio Pharmaceuticals is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Phio Pharmaceuticals has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.47% of the float of Phio Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Phio Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Phio Pharmaceuticals has recently decreased by 32.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Phio Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Phio Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.47% of the float of Phio Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Phio Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Phio Pharmaceuticals has recently decreased by 32.31%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.96

News Sentiment

Phio Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Phio Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

8 people have searched for PHIO on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Phio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Phio Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.89% of the stock of Phio Pharmaceuticals is held by insiders.

Percentage Held by Institutions

57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHIO Stock Analysis - Frequently Asked Questions

How have PHIO shares performed this year?

Phio Pharmaceuticals' stock was trading at $1.80 at the beginning of the year. Since then, PHIO stock has increased by 19.2% and is now trading at $2.1450.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) issued its earnings results on Thursday, August, 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09.

When did Phio Pharmaceuticals' stock split?

Phio Pharmaceuticals's stock reverse split on the morning of Friday, July 5th 2024.The 1-9 reverse split was announced on Friday, July 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split.

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' top institutional investors include Geode Capital Management LLC (1.20%) and Cetera Investment Advisers (0.68%). Insiders that own company stock include Robert J Bitterman and Robert L Ferrara.
View institutional ownership trends.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Phio Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Phunware (PHUN) and Virgin Galactic (SPCE).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHIO
• CIK: 1533040
• Web: phiopharma.com
• Phone: (508) 767-3861
• Fax: 508-767-3862
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Phio Pharmaceuticals: $14.00
• High Price Target: $14.00
• Low Price Target: $14.00
• Potential Upside/Downside: +554.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -88.75%
• Return on Assets: -77.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.36
• Quick Ratio: 9.36

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 3.10

Miscellaneous

• Outstanding Shares: 5,730,000
• Free Float: 5,676,000
• Market Cap: $12.26 million
• Optionable: Not Optionable
• Beta: 0.89